Can new tests predict who will develop active TB?
NCT ID NCT06221488
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study follows 300 health workers in Cape Town, South Africa, who are at high risk of tuberculosis (TB) infection. Researchers will use a combination of existing and new tests every three months to track immune responses at the time of infection. The goal is to better understand why some people with TB infection develop active, life-threatening TB disease while others do not, which could improve prevention strategies.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- If successful, this research could help identify which people with TB infection are at highest risk of developing active TB disease, allowing for better targeting of preventive treatments.
- What could go wrong
- This is an observational study, not a treatment trial. It aims to gather knowledge, not test a cure or therapy. The findings may not apply to all populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Jan 2024
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will be health workers (primarily clinical but may include support staff) who are \>18 years of age.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * ≥18 years old * Health worker * Able to provide informed consent Exclusion Criteria: * Prior history of TB or known prior positive IGRA * Current or prior history of taking anti-TB treatment
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Tuberculosis are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Stellenbosch University
RECRUITINGCape Town, South Africa
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Effects of adjunct Omega-3 long-chain polyunsaturated fatty acids in pulmonary tuberculosis patients: an early bactericidal activity and inflammatory activity trial
- A randomized clinical trial of early empiric Anti-Mycobacterium tuberculosis therapy for sepsis in Sub-Saharan africa
- An open-label, randomized controlled trial of the new one-month regimen versus the current three-month regimen for the treatment of tuberculosis infection in vietnam
- Can a TB infection leave a mark on the placenta?
- Can a 4-Drug combo cut TB treatment time in half?
- Can a short talk therapy boost TB recovery?